{
    "symbol": "VTRS",
    "slug": "vtrs",
    "display_name": "VTRS",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/vtrs",
    "lang": "en",
    "as_of": "2026-07-22T01:13:29+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 0,
        "inferred": 1,
        "avg_impact": 8,
        "avg_confidence": 78,
        "last_signal_at": "2026-07-22 01:16:50",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Broad tariff shock to generic drug sector",
            "count": 1
        },
        {
            "text": "Investor caution on drug manufacturing stocks",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Viatris' diversified portfolio mitigates pure generic risk",
            "count": 1
        },
        {
            "text": "Potential government subsidies for domestic pharma",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-07-22 01:16:50",
            "sentiment": "Bearish",
            "impact_score": 8,
            "confidence_score": 78,
            "mention_type": "inferred",
            "timeframe": "mid-term",
            "region": "US",
            "reasoning": "Viatris, another major generic drug producer, is inferred to be affected similarly to Teva, with significant exposure to imported generics. The article's discussion of widespread industry impact implies a bearish outlook for VTRS.",
            "article": {
                "title": "Trump Plans 100% Tariff on Generic Drugs Starting August 2028",
                "url": "https://finscans.com/news/trump-plans-100-tariff-on-generic-drugs-starting-august-2028"
            }
        }
    ]
}